Микстура
Основна информация
- Търговско наименование:
- Микстура Алба Гален Фарма 4 g/40 g дермална суспенсия
- Активна съставка:
- Цинков Оксид
- Предлага се от:
- Гален Фарма ООД
- АТС код:
- D02AB
- INN (Международно Name):
- Zinc oxide
- Използвай за:
- Хората
- Вид на лекарството:
- алопатични наркотици
Документи
- за медицински специалисти:
- кратка характеристика на продукта
-
- за широката общественост:
- Информационната листовка на този продукт в момента не е на разположение, можете да изпратите заявка за нашето обслужване на клиенти и ние ще Ви уведомим веднага щом ние сме в състояние да го получи.
Искане на информационната листовка за широката общественост.
Локализация
- Предлага се в:
-
България
- Език:
- български
Терапевтична информация
- Каталог на резюме:
- Mixtura alba Galen Pharma, 4 g/40 g cutaneous suspension
Друга информация
Състояние
- Източник:
- Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
- Номер на разрешението:
- 20030688
- Дата Оторизация:
- 20-05-2011
- Последна актуализация:
- 01-06-2018
кратка характеристика на продукта
- Информационната листовка на този продукт в момента не е на разположение, можете да изпратите заявка за нашето обслужване на клиенти и ние ще Ви уведомим веднага щом ние сме в състояние да го получи.
Искане на информационната листовка за широката общественост.
Документи на други езици са налични тук
- Достъпът до този документ е достъпен само за регистрирани потребители.
Регистрирайте се сега за пълен достъп
16-7-2018
Orphan designation: Arsenic trioxide, for the: Treatment of graft-versus-host disease
Europe - EMA - European Medicines Agency
12-6-2018
Blokhuis: harde feiten gif in sigaretten zeer zorgelijk
Teer, nicotine en koolmonoxide gehalten in sigaretten die gemeten worden volgens de Canadian Intense (CI) methode zijn minimaal twee keer zo hoog als de gehalten gemeten met de wettelijke voorgeschreven ISO methode waarmee de EU en dus ook Nederland werkt. In sommige gevallen liggen de gehaltes zelfs tot meer dan 20 keer hoger. Dat blijkt uit onderzoek van het RIVM, dat 100 sigaretten onder de loep nam. Staatssecretaris Paul Blokhuis (VWS) heeft als opdrachtgever het onderzoek vandaag in ontvangst genome...
Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport
21-5-2018
Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir by MBI Distributing: Recall - Due to a Lack of Adequate Controls
Manufacturing products without proper process controls increases the probability that products will vary in strength, quality and purity
FDA - U.S. Food and Drug Administration
18-5-2018
MBI Distributing, Inc. Issues Voluntary Nationwide Recall of Homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir Due to a Lack of Process Controls
MBI Distributing, Inc. is voluntarily recalling all lots of homeopathic Teething Drops, Nausea Drops, Intestinal Colic Drops, Stomach Calm, Expectorant Cough Syrup, Silver-Zinc Throat Spray, and Argentum Elixir, within expiry, to the consumer level. The drug products have been found to be manufactured with a lack of adequate controls.
FDA - U.S. Food and Drug Administration
17-5-2018
Orphan designation: adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1, for the: Treatment of amyotrophic lateral sclerosis
Europe - EMA - European Medicines Agency
3-5-2018
Orphan designation: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene, for the: Treatment of mucopolysaccharidosis type I
Europe - EMA - European Medicines Agency
3-5-2018
Orphan designation: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene, for the: Treatment of mucopolysaccharidosis type II (Hunter's syndrome)
Europe - EMA - European Medicines Agency
2-5-2018
Human medicines European public assessment report (EPAR): Velphoro, mixture of polynuclear iron(III)-oxyhydroxide, sucrose and starches, Revision: 5, Authorised
Europe - EMA - European Medicines Agency
6-7-2017
The European Commission's decision concerning veterinary medicinal products containing zinc oxide
On 26 June 2017, the European Commission adopted a decision to withdraw all marketing authorisations for veterinary medicinal products containing zinc oxide administered orally to food producing species. The medicinal products affected by the decision appear from Annex I to the decision.
Danish Medicines Agency
21-3-2017
New recommendation for phasing out zinc oxide for young pigs
The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has confirmed a previous decision to phase out zinc oxide. Consequently, the CVMP has once more recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.
Danish Medicines Agency
5-1-2017
Re-examination of the CVMP's decision to phase out zinc oxide for young pigs
The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) will re-examine the decision to phase out medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs.
Danish Medicines Agency
19-12-2016
Zinc oxide for young pigs to be phased out
The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.
Danish Medicines Agency
4-5-2009
Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)
Danish Medicines Agency
12-6-2018
EU/3/17/1956 (Sangamo Therapeutics UK LTD)
EU/3/17/1956 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene) - Transfer of orphan designation - Commission Decision (2018)3811 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/168/17/T/01
Europe -DG Health and Food Safety
12-6-2018
EU/3/17/1955 (Sangamo Therapeutics UK LTD)
EU/3/17/1955 (Active substance: Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene) - Transfer of orphan designation - Commission Decision (2018)3810 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/167/17/T/01
Europe -DG Health and Food Safety
16-5-2018
Bravecto Plus (Intervet International B.V.)
Bravecto Plus (Active substance: fluralaner / moxidectin) - Centralised - Authorisation - Commission Decision (2018)3019 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4440
Europe -DG Health and Food Safety
3-5-2018
Trisenox (Teva B.V.)
Trisenox (Active substance: Arsenic trioxide) - Centralised - Yearly update - Commission Decision (2018)2778 of Thu, 03 May 2018
Europe -DG Health and Food Safety
18-4-2018
EU/3/18/2008 (StolmAr and Partner PatentanwAlte PartG mbB)
EU/3/18/2008 (Active substance: Adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1) - Orphan designation - Commission Decision (2018)2404 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/254/17
Europe -DG Health and Food Safety
16-3-2018
Pending EC decision: Bravecto Plus,   fluralaner / moxidectin  , Opinion date: 15-Mar-2018
Europe - EMA - European Medicines Agency